Clinical Best Practices for Radiation Safety During Lutetium-177 Therapy.

IMPORTANCE: 177 Lu therapy as part of theranostic treatment for cancer is expanding but it can be a challenge for sites with limited radiation protection staff to implement the radiation safety program required for therapeutic nuclear medicine. OBJECTIVE: To increase the adoption of 177 Lu therapy, especially in smaller centers and clinics, by providing a collection of radiation safety best practices and operational experience. To provide a resource for radiation safety officers supporting the implementation of a 177 Lu therapy program. METHODS: A panel of 11 radiation safety professionals representing sites across Canada and the United States with experience delivering 177 Lu therapy was assembled and discussed their responses to a list of questions focused on the following radiation safety topics: facility layout and design; radiation safety program; and drug management and patient care. RESULTS: A comprehensive set of best practice guidelines for clinical radiation safety during 177 Lu therapy has been developed based on the collective operational experience of a group of radiation safety professionals. Significant findings included that 177 Lu therapy is often safely administered in unshielded rooms, that staff radiation exposure associated with 177 Lu therapy is minimal relative to other nuclear medicine programs, and that some relatively simple preparation in advance including papering of common surfaces and planning for incontinence can effectively control contamination during therapy. CONCLUSION: The guidance contained in this paper will assist radiation safety professionals in the implementation of safe, effective 177 Lu therapy programs, even at smaller sites with limited to no experience in therapeutic nuclear medicine.

Quantitative evaluation of PSMA PET imaging using a realistic anthropomorphic phantom and shell-less radioactive epoxy lesions.

BACKGROUND: Positron emission tomography (PET) with prostate specific membrane antigen (PSMA) have shown superior performance in detecting metastatic prostate cancers. Relative to [18F]fluorodeoxyglucose ([18F]FDG) PET images, PSMA PET images tend to visualize significantly higher-contrast focal lesions. We aim to evaluate segmentation and reconstruction algorithms in this emerging context. Specifically, Bayesian or maximum a posteriori (MAP) image reconstruction, compared to standard ordered subsets expectation maximization (OSEM) reconstruction, has received significant interest for its potential to reach convergence with minimal noise amplifications. However, few phantom studies have evaluated the quantitative accuracy of such reconstructions for high contrast, small lesions (sub-10 mm) that are typically observed in PSMA images. In this study, we cast 3 mm-16-mm spheres using epoxy resin infused with a long half-life positron emitter (sodium-22; 22Na) to simulate prostate cancer metastasis. The anthropomorphic Probe-IQ phantom, which features a liver, bladder, lungs, and ureters, was used to model relevant anatomy. Dynamic PET acquisitions were acquired and images were reconstructed with OSEM (varying subsets and iterations) and BSREM (varying ß parameters), and the effects on lesion quantitation were evaluated. RESULTS: The 22Na lesions were scanned against an aqueous solution containing fluorine-18 (18F) as the background. Regions-of-interest were drawn with MIM Software using 40% fixed threshold (40% FT) and a gradient segmentation algorithm (MIM's PET Edge+). Recovery coefficients (RCs) (max, mean, peak, and newly defined "apex"), metabolic tumour volume (MTV), and total tumour uptake (TTU) were calculated for each sphere. SUVpeak and SUVapex had the most consistent RCs for different lesion-to-background ratios and reconstruction parameters. The gradient-based segmentation algorithm was more accurate than 40% FT for determining MTV and TTU, particularly for lesions [Formula: see text] 6 mm in diameter (R2 = 0.979-0.996 vs. R2 = 0.115-0.527, respectively). CONCLUSION: An anthropomorphic phantom was used to evaluate quantitation for PSMA PET imaging of metastatic prostate cancer lesions. BSREM with ß = 200-400 and OSEM with 2-5 iterations resulted in the most accurate and robust measurements of SUVmean, MTV, and TTU for imaging conditions in 18F-PSMA PET/CT images. SUVapex, a hybrid metric of SUVmax and SUVpeak, was proposed for robust, accurate, and segmentation-free quantitation of lesions for PSMA PET.

Effects of 10 MV and Flattening-Filter-Free Beams on Peripheral Dose in a Cohort of Pediatric Patients.

PURPOSE: To assess the effect of flattening-filter-free (FFF) and 10 MV radiation therapy beams on the peripheral dose received by a population of pediatric patients undergoing volumetric modulated arc therapy (VMAT). METHODS AND MATERIALS: Twenty-six previously delivered 6 MV flattened VMAT pediatric radiation therapy treatments plans were replanned with 6 MV flattened, 6 MV FFF, and 10 MV FFF VMAT. Monte Carlo simulation code EGSnrc was used in conjunction with a measurement-based model to obtain 3-dimensional dose distributions. Peripheral dose delivered by FFF beams was compared with that delivered by 6 MV flattened beams. A statistical analysis was performed to determine whether certain clinical factors (eg, target volume, location) were associated with a change in integral relative radiation dose. Neutron dose measurements assessed the neutron contribution from the 6 MV flattened and 10 MV FFF x-ray beams. RESULTS: Both the 6 MV FFF and 10 MV FFF beams delivered significantly lower peripheral radiation doses than 6 MV flattened (P < .01). The dose reduction was of 3.9% (95% confidence interval [CI] 2.1-5.7) and 9.8% (95% CI, 8.0-11.6) at 5 cm from the PTV and 21.9% (95% CI, 13.7-30.1) and 25.6% (95% CI, 17.6-33.6) at 30 cm for 6 MV FFF and 10 MV FFF beams, respectively. The clinical factors examined did not have a significant effect on the relative magnitude of the peripheral dose reduction. The upper limit on the neutron dose was determined to be 203 µSv for the 6 MV flattened and 522 µSv for the 10 MV FFF beam. CONCLUSIONS: Both FFF beams significantly (P < .01) reduced the peripheral dose. 10 MV FFF was more effective at reducing peripheral dose at distances <5 cm from the PTV edge. The neutron doses delivered by all beams were <1% compared with the photon doses. 10 MV FFF should be used to minimize peripheral dose.

A comparison of two commercial treatment-planning systems to IMRT.

This study compared the clinical functionality of BrainSCAN (BrainLAB) and Helios (Eclipse, Varian) for intensity-modulated radiation therapy (IMRT) treatment planning with the aim of identifying practical and technical issues. The study considered implementation and commissioning, dose optimization, and plan assessment. Both systems were commissioned for the same 6 MV photon beam equipped with a high-resolution multileaf collimator (Varian Millennium 120 leaf). The software was applied to three test plans having identical imaging and contour data. Analysis considered 3D axial dose distributions, dose-volume histograms, and monitor unit calculations. Each system requires somewhat different input data to characterize the beam prior to use, so the same data cannot be used for commissioning. In addition, whereas measured beam data was entered directly into Helios with minimal data processing, the BrainSCAN system required configured beam data to be sent to BrainLAB before clinical use. One key difference with respect to system commissioning was that BrainSCAN required high resolution data, which necessitated the use of detectors with small active volumes. This difference was found to impact on the ability of the systems to accurately calculate dose for highly modulated fields, with BrainSCAN being more successful than Helios. In terms of functionality, the BrainSCAN system uses a dynamically penalized likelihood inverse planning algorithm and calculates four plans at once with various relative weighting of the planning target and organ-at-risk volumes. Helios uses a gradient algorithm that allows the user to make changes to some of the input parameters during optimization. An analysis of the dosimetry output shows that, although the systems are different in many respects, they are each capable of producing substantially equivalent dose plans in terms of target coverage and normal tissue sparing.